Novartis reports nine tumor cases in patients treated with Zolgensma gene therapy

Novartis has confirmed that nine cases of tumors have been reported in patients who received its spinal muscular atrophy gene therapy, Zolgensma. The company says two cases are confirmed and seven are considered likely related to the treatment.

Patient advocates are raising concerns on social media, noting that families were informed through a “tiered rollout” of information rather than a public announcement. One parent described learning of the issue during a recent neurologist visit and shared the news on LinkedIn.

The reports have prompted calls for greater transparency from Novartis, with advocates accusing the company of withholding details. No regulatory action has been announced yet, but the safety signals are being closely monitored.

The situation adds to ongoing scrutiny of Zolgensma, which has faced controversy since its launch. Stakeholders in the biotech and investment communities are watching the developments for potential impact on the therapy’s market outlook.